Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. demonstrated strong performance in Q4, with shares rising approximately 7% in the after-market following impressive results and positive revenue guidance, alongside operating margin expansion projected to exceed 16%. The company is poised for growth driven by new product launches, accelerated adoption rates in heart and lung transplants, and robust international market expansion, alongside favorable trends in organ utilization. Additionally, TransMedics is establishing a new standard of care within the organ transplant sector, presenting substantial value creation potential in the years ahead despite increasing competition.

Bears say

TransMedics Group Inc. is facing a negative outlook primarily due to projected declines in operating margins, anticipated to drop by 250 basis points this year as a result of significant investments in its clinical pipeline and international infrastructure. While the company reported strong revenue growth in its liver franchise, the overall product and service revenues fell short of consensus expectations, with significant underperformance in gross margins at 58.8%, missing targets by 180 basis points. Additional risks such as potential market share loss from increasing competition, reimbursement changes, and challenges in clinical trial execution further contribute to the financial uncertainties surrounding the company's future performance.

TMDX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 9 analysts, TMDX has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $154, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $154, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.